MRK vs CRL
By Alex · Tickerpine
Merck & Co., Inc. vs Charles River Laboratories International, Inc., side by side — the numbers that matter, in plain English. No “winner” hype; you decide.
| Metric | MRK | CRL |
|---|---|---|
| Price | $147.76 | $337.97 |
| Market cap | $364.26B | $16.19B |
| P/E ratio | 149.3 | 367.4 |
| ROE | 5.06% | 1.27% |
| Profit margin | 3.64% | 1.01% |
| Revenue growth | 4.70% | -2.20% |
| Dividend yield | 2.30% | 0.00% |
| Beta | 0.12 | 1.34 |
Green = the more favorable figure for that metric (lower P/E, higher ROE, margin, growth and yield). Not a recommendation.
MRK vs CRL in plain English
- MRK is the bigger company — about 22.5× the market cap of CRL.
- MRK is cheaper on earnings (P/E 149.3 vs 367.4).
- MRK earns a higher return on equity (5% vs 1%).
- MRK is growing revenue faster (5% vs -2%).
- MRK pays a dividend (2.30%) while the other effectively doesn't.
How would $1,000 have done in each?
MRK return calculator
See what $1,000 in Merck & Co., Inc. would be worth today.
CRL return calculator
See what $1,000 in Charles River Laboratories International, Inc. would be worth today.
Figures from public market data, may be delayed. Comparison is informational only — not investment advice.